G-CSF/PEG-G-CSF Market 2023-2030 Size, Industry Report Analysis, Future Demands, Growth, Share, Application, Segmentation, & Business Opportunities

 The comprehensive G-CSF/PEG-G-CSF Market report endows with statistics on the current state of the industry and hence works as a valuable source of guidance and direction for companies and investors interested in this market. To have finest market insights and knowhow of the most excellent market opportunities into the specific markets, this market research report is an ideal option. The report proves to be a thorough synopsis on the study, analysis and estimation of the market and how it is affecting the Healthcare industry. Besides, G-CSF/PEG-G-CSF Market market report comprises of an extensive evaluation of the market’s growth prospects and restrictions.

Recent Developments

·        In July 2018, Accord Healthcare, a subsidiary of Intas Pharmaceuticals Ltd., launched a pegfilgrastim biosimilar across Europe after being given Green Light for Pelgraz® (pegfilgrastim) by CHMP (Committee for Medicinal Products for Human Use). This product launched helped the company to expand their business across Europe.

·        In March 2022, Kashiv Biosciences announced the approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen by U.S. Food and Drug Administration (FDA). The product is marketed under the proprietary name RELEUKO.

Drivers

·        Growing incidences of blood cancers and cancer diseases

Cancer is a general term for many diseases that can affect any part of the body. Other terms used for cancer are malignant tumors and neoplasm. One of the characteristics of cancer is the rapid formation of abnormal cells that grow beyond normal limits and can invade neighboring parts of the body and spread to other organs; the latter process is called metastasis. Extensive metastases are the leading cause of cancer death.

Filgrastim is a granulocyte colony-stimulating factor (GCSF) that helps increase the number of neutrophils in the blood. Filgrastim and pegfilgrastim are highly used to increase white blood cells after cancer chemotherapy or radiation therapy.

·        Increasing cases of febrile neutropenia

Febrile neutropenia refers to fever during significant neutropenia. If a patient is neutropenic, their risk of infection may be higher than usual, and the severity of a particular infection may also be higher. Febrile neutropenia is the most common life-threatening complication of cancer treatment; its treatment is often an oncological emergency.

Febrile neutropenia is neutropenia accompanied by fever. Neutropenia refers to a decrease in the concentration of neutrophils in the blood. Neutrophils are a type of white blood cell that help fight infections as part of the immune system. The Infectious Diseases Society of America defines neutropenia as an absolute neutrophil count (ANC) of less than 1500 cells/mm3. The risk of infection and neutropenic fever increases dramatically with severe neutropenia, defined as an absolute neutrophil count (ANC) of less than 500 cells/mm3. Fever is defined as a single oral temperature greater than or equal to 101° Fahrenheit (38.3° Celsius) or a persistent temperature greater than or equal to 100.4° Fahrenheit (38.0° Celsius) or greater for one hour or longer.

Opportunity

·        The use of biosimilars helps reduce healthcare costs for patients

Biosimilars have the potential to fundamentally change healthcare by providing more affordable, equally effective treatments for patients and providing more treatment options for physicians. Developing biosimilars requires rigorous analysis to demonstrate their equivalence to the reference product and ensure no clinically meaningful differences in their safety, efficacy, and purity. As a result, health systems can channel long-term savings into overall improvements in patient care. To help create a thriving biosimilar market and ensure patient access, policymakers can take steps to reduce or eliminate the cost of biosimilars and encourage physicians to prescribe biosimilars compared to Europe.

The Global G-CSF/PEG-G-CSF market is Dominated by Firms Such as:

USV Private Limited, Viatris Inc., Biocon, Fresenius Kabi AG, Hangzhou Jiuyuan Gene Engineering Co., Ltd., Amgen Inc., Pfizer Inc., Sandoz International GmbH, Apotex Inc., Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Coherus BioSciences, Accord Healthcare, NAPP PHARMACEUTICALS LIMITED., Intas Pharmaceuticals Ltd., Mundipharma International, Teva Pharmaceutical Industries Ltd., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd

Market Segmentation: G-CSF/PEG-G-CSF Market

GLOBAL G-CSF / PEG-G-CSF MARKET, BY INDICATION

·        Neutropenia

·        Oncology

·        Chronic And Autoimmune Diseases

·        Blood Disorders

·        Growth Hormone Deficiency

·        Others

On the basis of indication the global G-CSF/PEG-G-CSF is further segmented into neutropenia, oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency and others.

GLOBAL G-CSF / PEG-G-CSF MARKET, BY DOSAGE

·        Mono

·        Combination

On the basis of dosage the global G-CSF/PEG-G-CSF is further segmented into mono and combination.

GLOBAL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION

·        Intravenous

·        Subcutaneous

On the basis of route of administration the global G-CSF/PEG-G-CSF is further segmented into intravenous and subcutaneous.

GLOBAL G-CSF / PEG-G-CSF MARKET, BY PACKAGING

·        Single Use Vials

·        Pre Filled Syringes

On the basis of packaging the global G-CSF/PEG-G-CSF is further segmented into single use vials and pre filled syringes.

GLOBAL G-CSF / PEG-G-CSF MARKET, BY END USER

·        Hospitals & Clinics

·        Research & Academic Institutes

·        Ambulatory Surgical Centers

·        Others

On the basis of end user the global G-CSF/PEG-G-CSF is further segmented into hospitals and clinics, research & academic institutes, ambulatory surgical centers and others.

GLOBAL G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL

·        Hospital Pharmacy

·        Online Pharmacy

·        Retail Pharmacy

·        Others

On the basis of distribution channel the global G-CSF/PEG-G-CSF is further segmented into hospital pharmacy, online pharmacy, retail pharmacy and others.

G-CSF/PEG-G-CSF Market Analysis and Insights

The increase in cancer prevention in developed countries and governments have introduced conscious initiatives to educate early treatment, promoting the global sales market of biosimilar G-CSF. Grafeel, Colstim, Neukine and Filcad, which are approved biosimilars and are also cost-effective and readily available in developing countries, will lead to significant market growth. China and India are the countries where the number of cancer patients is increasing, which is likely to boost the global market. Thus, the use of biosimilars helps in reducing the healthcare costs of patients compared to the use of original biologics, which increases the demand in the global G-CSF Biosimilars sales market. Due to the complex biological manufacturing processes of individual biosimilars, the costs of biosimilars are not as low as generics.  Growing prevalence of autoimmune and rare chronic diseases is expected to drive the segmental market’s growth.

Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/reports/global-g-csf-peg-g-csf-market

Highlights the following key factors:

Business description – A detailed description of the company’s operations and business divisions

Corporate strategy – Analyst’s summarization of the company’s business strategy

SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats

Company history – Progression of key events associated with the company

Major products and services – A list of major products, services and brands of the company

Key competitors – A list of key competitors to the company

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company year’s history

Explore More Reports:-

Europe G-CSF/PEG-G-CSF Market https://www.databridgemarketresearch.com/reports/europe-g-csf-peg-g-csf-market

Asia-Pacific G-CSF/ PEG-G-CSF Market https://www.databridgemarketresearch.com/reports/asia-pacific-g-csf-peg-g-csf-market

Latin America G-CSF/ PEG-G-CSF Market https://www.databridgemarketresearch.com/reports/latin-america-g-csf-peg-g-csf-market

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Contact US:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com